Navigation Links
Research improves diagnosis and treatment of bleeding disorder

A rare bleeding disorder that can lead to life-threatening bleeding episodes is misdiagnosed in 15 per cent of cases according to findings from a new international research project led by a Queen's professor.

"Correct diagnosis is critical because it determines the treatment decision," says Maha Othman, a professor in the Department of Anatomy and Cell Biology who led the three-year research project on the rare platelet type of von Willebrand disease (VWD).

Patients with VWD are commonly treated with drugs that help control their condition. However, these drugs aggravate bleeding in patients with the rarer platelet form of the disease, and misdiagnosis can leave these patients vulnerable to severe life-threatening bleeding episodes in situations like pregnancy and surgical operations.

Although both forms of VWD are genetic disorders that share many diagnostic features, the defect actually lies in two different genes. A correct diagnosis can only be made by closely examining certain areas of both genes to determine where the defect lies.

Dr. Othman's study is the first large study to investigate the occurrence of the two types of VWD worldwide and to evaluate DNA analysis as a diagnostic tool.

In addition to pioneering this international project, Dr. Othman has also created an online registry aimed at determining the frequency of the rare platelet form of VWD and to collect data about the disorder. Despite its relative rarity, VWD is actually the most common genetically inherited bleeding disorder, affecting about one per cent of the general population.

Dr. Othman's research will be published in the March issue of the Thrombosis and Haemostasis Journal.


Contact: Christina Archibald
Queen's University

Page: 1

Related biology news :

1. NIDCD research at ARO Midwinter Meeting
2. MU researchers believe discovery could lead to testing that displaces colonoscopies
3. Researchers link gene mutations to Ebsteins anomaly
4. Whitehead member Rudolf Jaenisch honored for groundbreaking stem cell research
5. UT researchers link algae to harmful estrogen-like compound in water
6. FASEB praises President Obama for increasing funding for research in his FY 2012 budget
7. Ben-Gurion U. researchers develop techniques to manipulate plant adaption in arid climates
8. Jefferson researchers provide genetic evidence that antioxidants can help treat cancer
9. Earliest humans not so different from us, research suggests
10. Researchers working toward automating sedation in intensive care units
11. U of Alberta researcher discovers potential cancer therapy target
Post Your Comments:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology: